Nephrol Dial Transplant (2014) 29: 2075–2084 doi: 10.1093/ndt/gfu201 Advance Access publication 2 June 2014
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia Iain C. Macdougall1, Andreas H. Bock2, Fernando Carrera3, Kai-Uwe Eckardt4, Carlo Gaillard5, David Van Wyck6, Bernard Roubert7, Jacqueline G. Nolen7, Simon D. Roger8 on behalf of the FIND-CKD Study Investigators† Department of Renal Medicine, King’s College Hospital, Denmark Hill, London SE5 9RS, UK, 2Department of Nephrology, Kantonsspital
Aarau, Aarau, Switzerland, 3Eurodial, DaVita, Leiria, Portugal, 4Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, 5Department of Nephrology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands, 6DaVita Healthcare Partners Inc., Denver, CO, USA, 7Vifor Pharma, Glattbrugg, Switzerland and 8Renal Research, Gosford, NSW, Australia
A B S T R AC T Background. The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. Methods. Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with nondialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400–600 μg/L) or lower (100–200 μg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia Iain C. Macdougall1, Andreas H. Bock2, Fernando Carrera3, Kai-Uwe Eckardt4, Carlo Gaillard5, David Van Wyck6, Bernard Roubert7, Jacqueline G. Nolen7, Simon D. Roger8 on behalf of the FIND-CKD Study Investigators† Department of Renal Medicine, King’s College Hospital, Denmark Hill, London SE5 9RS, UK, 2Department of Nephrology, Kantonsspital
Aarau, Aarau, Switzerland, 3Eurodial, DaVita, Leiria, Portugal, 4Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, 5Department of Nephrology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands, 6DaVita Healthcare Partners Inc., Denver, CO, USA, 7Vifor Pharma, Glattbrugg, Switzerland and 8Renal Research, Gosford, NSW, Australia
A B S T R AC T Background. The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. Methods. Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with nondialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400–600 μg/L) or lower (100–200 μg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values
